
Early COVID Vaccine Results Bode Well for an Approval This Year
The data are preliminary, however, and it is not yet clear whether the vaccine protects against severe disease
The data are preliminary, however, and it is not yet clear whether the vaccine protects against severe disease
Therapeutic and diagnostic apps and bots are almost here
Replacing humans with digital simulations could make clinical trials faster and safer
Fewer trips to medical labs make care more accessible
Genetic engineering could allow for speedy production as well
Book recommendations from the editors of Scientific American
Scientific American’s senior medicine editor Josh Fischman talks about issues in medicine and public health that will be affected by this election.
Hospital workers who got vaccinated were significantly less likely to develop COVID than those who did not
Cancer is not a disease fought alone. The stronger the community, the better the outcomes for all.
Voters must decide whether to keep financing the second largest funder of stem cell science in the world
They highlight one of the biggest problems in American health care
Despite conflicting data, the highly anticipated results will make the treatment a standard of care in the U.S.
Proponents of the trials say they can be run safely and help to identify effective vaccines, but others have questioned their value
A vaccine made by Pfizer could seek emergency approval by the third week of November, but it likely won’t be available to the public until mid- to late 2021
A medical student describes winning her fight to change an equation that prevented Black people from getting crucial treatment
It’s not just “antiscience thinking”
Synthetic peptides that mimic human antibodies for COVID-19 could be cheaper and easier to produce
A stretch of Neandertal DNA has been associated with some cases of severe COVID-19, but it’s unclear how much of a risk it poses. Christopher Intagliata reports.
China has promised vaccines to many countries, but whether it can meet its commitments is unclear
New Nobel laureate in chemistry Jennifer Doudna talks about various applications of the gene-editing tool CRISPR.
Support science journalism.
Thanks for reading Scientific American. Knowledge awaits.
Already a subscriber? Sign in.
Thanks for reading Scientific American. Create your free account or Sign in to continue.
Create Account